UBS raised the firm’s price target on Kymera Therapeutics (KYMR) to $128 from $90 and keeps a Buy rating on the shares.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KYMR:
- Kymera Therapeutics price target raised to $100 from $95 at Stephens
- Kymera: Expanding Degrader Pipeline and Early Clinical Validation Support Buy Rating and Favorable Risk‑Reward
- Kymera Therapeutics price target raised to $120 from $110 at Citi
- Kymera Therapeutics Signals Strong Momentum In Earnings Call
- Kymera’s KT-579 Enters First-in-Human Testing: What Early Trial Progress Means for Investors